Dear Editor,
As we all know that COVID-19 has created a grave situation ever since the inception of pandemic in Nov 2019. To curb the situation, the mankind worked tirelessly and produced vaccines with the vision of mass vaccination. However, an extremely rare vaccine associated adverse event was observed in a sparse subpopulation of individuals especially those who received adenoviral vector-based vaccines. This complication was termed as Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT).
Anzeige
In this context, I would like to bring to your notice that the first confirmed case from India was reported by Mishra et al. in his article titled “COVID-19 Vaccine-Induced Thrombosis and Thrombocytopenia: First Confirmed Case from India” [1]. The index case was confirmed as per the recommended guidelines of American Society of Hematology using a functional assay i.e. platelet activation test for heparin induced thrombocytopenia and thrombosis (HITT) which is also the recommended testing modality for diagnosing VITT. The article under reference was submitted to the Indian Journal of Hematology and Blood Transfusion on 11th August 2021 and was accepted on 18th September 2021. The same was published online on 29th September 2021.
The article titled “Vaccine-Induced Thrombotic Thrombocytopenia (VITT): First Report from India” by John et al. was published in your esteemed journal [2]. This submission was received by your journal on 19th September 2021, which was accepted by your journal on 17th February 2022 and published online on 04th March 2022. Hence, the title of this article and the discussion contained in it doesn’t vindicate the fact that it is actually the first report from India.
You are requested to delve into this matter and make necessary refinements so that the article in reference number 1 gets the due credit and the article printed in your journal looks error-free.
Declarations
Ethics approval and consent to participate
Not applicable.
Anzeige
Consent for publication
Not applicable.
Competing interests
The authors declare no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.